Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 11
Submit an article Journal homepage
62
Views
30
CrossRef citations to date
0
Altmetric
Research Article

Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes

Satoru Kikuchi Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Kazuo Muroi Division of Cell Transplantation and Transfusion Jichi Medical School Minamikawachi Japan
,
Satoko Takahashi Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Chizuru Kawano-Yamamoto Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Masaaki Takatoku Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Akira Miyazato Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Tadashi Nagai Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Masaki Mori Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
,
Norio Komatsu Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
&
Keiya Ozawa Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
 show all
Pages 2349-2351 | Published online: 01 Jul 2009

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Aisling Nee & Jeffrey H. Lipton. (2019) Update on the management of chronic myeloid leukemia: current best practice and future directions. Expert Opinion on Orphan Drugs 7:4, pages 157-169.
Read now
K. Ikeda, Y. Shiga, A. Takahashi, T. Kai, H. Kimura, K. Takeyama, H. Noji, K. Ogawa, A. Nakamura, H. Ohira, Y. Sato & Y. Maruyama. (2006) Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leukemia & Lymphoma 47:1, pages 155-157.
Read now
Rie Yamazaki, Shinichiro Okamoto, Chien-Kang Chen, Shinichiro Tada, Hidetane Saito, Rie Shibata, Michiie Sakamoto, Takehiko Mori & Yasuo Ikeda. (2006) Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leukemia & Lymphoma 47:7, pages 1427-1430.
Read now

Articles from other publishers (27)

Seyyed Javad Boskabadi, Ayat Dashti, Sara Karevan, Saeed Kargar-Soleimanabad & Ebrahim Salehifar. (2023) Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review. Journal of Oncology Pharmacy Practice, pages 107815522311747.
Crossref
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter & Cosmin Sebastian Voican. (2021) Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology 157, pages 103127.
Crossref
Asmaa Atteya, Aiman Ahmad, Dima Daghstani, Kamran Mushtaq & Mohamed A. Yassin. (2020) Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 27:1, pages 107327482097659.
Crossref
Shefali Chopra & Romil Saxena. (2018) Drug-Induced Liver Injury—Perspectives from Pathology. Current Pharmacology Reports 4:3, pages 182-192.
Crossref
Ahmet Taner Sümbül & Özgür Özyılkan. 2018. The MASCC Textbook of Cancer Supportive Care and Survivorship. The MASCC Textbook of Cancer Supportive Care and Survivorship 445 465 .
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann & R E Clark. (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:8, pages 1648-1671.
Crossref
Helen Gharwan & Hunter Groninger. (2015) Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nature Reviews Clinical Oncology 13:4, pages 209-227.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 22 24 .
Kurt Fisher, Raj Vuppalanchi & Romil Saxena. (2015) Drug-Induced Liver Injury. Archives of Pathology & Laboratory Medicine 139:7, pages 876-887.
Crossref
Ralph Yachoui. (2014) Early Onset Imatinib Mesylate–Induced Hepatotoxicity in a Patient With Gastrointestinal Stromal Tumors. American Journal of Therapeutics 21:5, pages e148-e150.
Crossref
Lars Harbaum, Andreas Marx, Eray Goekkurt, Philippe Schafhausen & Djordje Atanackovic. (2013) Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. International Journal of Hematology 99:1, pages 91-94.
Crossref
Rashmi R. Shah, Joel Morganroth & Devron R. Shah. (2013) Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives. Drug Safety 36:7, pages 491-503.
Crossref
I. Diallo, S. B. Gning, F. Fall, B. Ndiaye, B. Fall, D. Irambona, M. Mbengue & P. S. Mbaye. (2011) Hépatotoxicité tardive à l’imatinib chez une patiente de 44 ansLate imatinib-mesylate induced hepatotoxicity in a 44 years old women. Journal Africain d'Hépato-Gastroentérologie 5:3, pages 214-216.
Crossref
Onder Tonyali, Ugur Coskun, Ramazan Yildiz, Tarkan Karakan, Umut Demirci, Nalan Akyurek, Mustafa Benekli & Suleyman Buyukberber. (2009) Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Medical Oncology 27:3, pages 768-773.
Crossref
. 2010. Meyler's Side Effects of Drugs in Cancer and Immunology. Meyler's Side Effects of Drugs in Cancer and Immunology 1 229 .
Baidehi Maiti, Sebouh Setrakian & Hamed A Daw. (2009) Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report. Cases Journal 2:1.
Crossref
Amani Asnacios, Sylvie Naveau & Gabriel Perlemuter. (2009) Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer 45, pages 332-342.
Crossref
Kosei Matsue, Takatoshi Aoki, Jun Odawara, Shun-ichi Kimura, Masayuki Yamakura & Masami Takeuchi. (2009) Haemorrhagic complications associated with reduced α2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Leukemia Research 33:6, pages 867-869.
Crossref
Eric W. Mueller, Michelle L. Rockey & Mitchell C. Rashkin. (2012) Sunitinib‐Related Fulminant Hepatic Failure: Case Report and Review of the Literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:8, pages 1066-1070.
Crossref
Yohann Loriot, Gabriel Perlemuter, David Malka, Frédérique Penault-Lorca, Valérie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand & Jean-Charles Soria. (2008) Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nature Clinical Practice Oncology 5:5, pages 268-278.
Crossref
Hans-Peter Lipp & Jörg Thomas Hartmann. 2008. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. A worldwide yearly survey of new data and trends in adverse drug reactions and interactions 520 532 .
Francisco Fuster, Luis Medina, Rolando Vallansot, Miquel Granell & Miquel Bruguera. (2007) Hepatitis tóxica por imatinib: descripción de dos casos y revisión de la literatura médica. Gastroenterología y Hepatología 30:9, pages 525-529.
Crossref
Edmundo A. Rodriguez-Frias & William M. Lee. (2007) Cancer Chemotherapy I: Hepatocellular Injury. Clinics in Liver Disease 11:3, pages 641-662.
Crossref
Ayse L. Mindikoglu, Arie Regev, Pablo A. Bejarano, Enrique J. Martinez, Lennox J. Jeffers & Eugene R. Schiff. (2007) Imatinib Mesylate (Gleevec) Hepatotoxicity. Digestive Diseases and Sciences 52:2, pages 598-601.
Crossref
Peter H. Wiernik. (2006) Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics 1:4, pages 539-567.
Crossref
Timothy J.S. Cross, Catherine Bagot, Bernard Portmann, Julia Wendon & D. Gillett. (2006) Imatinib mesylate as a cause of acute liver failure. American Journal of Hematology 81:3, pages 189-192.
Crossref
Katsuya Ikuta, Yoshihiro Torimoto, Junko Jimbo, Junki Inamura, Motohiro Shindo, Kazuya Sato, Yoshihiko Tokusashi, Naoyuki Miyokawa & Yutaka Kohgo. (2005) Severe Hepatic Injury Caused by Imatinib Mesylate Administered for the Treatment of Chronic Myeloid Leukemia and the Efficacy of Prednisolone for its Management. International Journal of Hematology 82:4, pages 343-346.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.